Discontinued — last reported Q4 '17
Corvex Indefinite-Lived Research and Development Assets decreased by 46.9% to $1.43M in Q4 2025 compared to the prior quarter. Over 3 years (FY 2022 to FY 2025), Indefinite-Lived Research and Development Assets shows relatively stable performance with a 0.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
indefinite_lived_rd_assets| Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|
| Value | $1.43M | $2.70M | $2.70M | $1.43M |
| QoQ Change | — | +88.5% | -0.1% | -46.9% |
| YoY Change | — | +88.5% | -0.1% | -46.9% |